公开(公告)号：US20220033522A1

公开(公告)日：2022-02-03

申请号：US17391744

申请日：2021-08-02

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Adam ZWOLAK ,  Ian WHITE ,  Ninkka TAMOT ,  Paul B. HARVILLA ,  Rajitha DODDAREDDY ,  Sanjaya SINGH ,  Martin Jack BORROK III

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10

Abstract: Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.

公开(公告)号：US11230609B2

公开(公告)日：2022-01-25

申请号：US16117522

申请日：2018-08-30

Applicant: JANSSEN BIOTECH, INC.

Inventor： Par Oskar Vilhelmsson Timmermand ,  Amanda Thuy Tran ,  Sven-Erik Strand ,  Urpo Juhani Lamminmaki ,  Kjell Sjostrom

IPC: C07K16/40 ,  C07K16/30 ,  A61K51/10 ,  A61K39/00

Abstract: The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.

公开(公告)号：US11208474B2

公开(公告)日：2021-12-28

申请号：US15813767

申请日：2017-11-15

Applicant: Janssen Biotech, Inc.

Inventor： Dennis Fitzgerald ,  Newman Yeilding ,  Jay Siegel

IPC: A61K39/395 ,  C07K16/24 ,  A61K9/00 ,  G01N33/00 ,  A61P17/06 ,  A61K31/519 ,  A61K45/06 ,  C07K16/28 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00

Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US11197913B2

公开(公告)日：2021-12-14

申请号：US16993556

申请日：2020-08-14

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC: A61K39/395 ,  C07K16/24 ,  A61K38/20 ,  A01K67/027 ,  A61K39/00 ,  C07K14/54 ,  A61K35/12

Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

公开(公告)号：US11180549B2

公开(公告)日：2021-11-23

申请号：US16717594

申请日：2019-12-17

Applicant: Janssen Biotech, Inc. ,  Applied Molecular Evolution, Inc.

Inventor： Yan Chen ,  Debra Gardner ,  David M. Knight ,  Michael W. Lark ,  Bailin Liang ,  David M. Marquis ,  David J. Shealy ,  Eric Michael Smith ,  Xiao-yu R. Song ,  Vedrana Stojanovic-Susulic ,  Raymond Sweet ,  Susan Tam ,  Alain P. Vasserot ,  Sheng-Jiun Wu ,  Jing Yang

IPC: A61K39/00 ,  C07K16/24

Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

公开(公告)号：US20210322323A1

公开(公告)日：2021-10-21

申请号：US17228753

申请日：2021-04-13

Applicant: Janssen Biotech, Inc.

Inventor： Jacqueline Maximilien ,  Gopal Rajan

IPC: A61K9/28 ,  A61K9/20 ,  A61K31/5377 ,  A61K9/00

Abstract: Provided herein are pharmaceutical compositions for oral administration comprising N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide or a pharmaceutically acceptable salt, hydrate, or solvate thereof as an active ingredient; and a combination of (i) a cellulose derivative and (ii) a sugar or polyol as diluents. The disclosed compositions are characterized by improved manufacturability, while maintaining the pharmaceutical benefits of minimizing the effect according to changes in pH environment in the stomach, possessing excellent stability, and exhibiting good bioavailability.

公开(公告)号：US11124565B2

公开(公告)日：2021-09-21

申请号：US16540388

申请日：2019-08-14

Applicant: Janssen Biotech, Inc.

Inventor： Joseph Hedrick ,  Elizabeth C. Hsia ,  Paul Imm ,  Jocelyn Leu ,  Bethany Paxson ,  Mark Rigby ,  Songmao Zheng ,  Ramineh Zoka

IPC: C07K16/24 ,  A61P3/10 ,  A61P29/00 ,  A61M5/00 ,  A61M5/315 ,  A61K39/00

Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D).

公开(公告)号：US20210284731A1

公开(公告)日：2021-09-16

申请号：US17202004

申请日：2021-03-15

Applicant: Janssen Biotech, Inc.

Inventor： Rajkumar Ganesan ,  Iqbal S. Grewal ,  Sanjaya Singh

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: Anti-TRGV9 molecules, such as anti-TRGV9 antibodies or antigen binding fragments thereof, are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.

公开(公告)号：US20210261636A1

公开(公告)日：2021-08-26

申请号：US17174590

申请日：2021-02-12

Applicant: Janssen Biotech, Inc.

Inventor： Vipul BHARGAVA ,  Vinod Krishna ,  Jaymala Patel ,  David J. Pocalyko ,  Yashoda Rani Rajpurohit ,  Pegah Safabakhsh ,  Manuel Alejandro Sepulveda

IPC: C07K14/47 ,  A61K39/00 ,  A61K45/06 ,  A61P37/04

Abstract: The disclosure relates to multiple myeloma neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the multiple myeloma neoantigens, and methods of making and using them.

公开(公告)号：US20210261609A1

公开(公告)日：2021-08-26

申请号：US17174505

申请日：2021-02-12

Applicant: Janssen Biotech, Inc.

Inventor： Vipul BHARGAVA ,  Vinod Krishna ,  David J. Pocalyko ,  Pegah Safabakhsh ,  Manuel Alejandro Sepulveda

IPC: C07K2/00 ,  A61K45/06 ,  C12N15/86 ,  C07K1/107

Abstract: The disclosure relates to ovarian cancer neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the ovarian cancer neoantigens, and methods of making and using them.